CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

HP:0100512: Low levels of vitamin DHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug88 Aspirin 81 mg Wiki 0.71
drug1231 Vitamin D Wiki 0.35

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D014808 Vitamin D Deficiency NIH 1.00
D004211 Disseminated Intravascular Coagulation NIH 0.41

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0005521 Disseminated intravascular coagulation HPO 0.41

There are 2 clinical trials

Clinical Trials

1 The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations

Although the novel SARS-CoV-2 virus (COVD-19) is classified as an acute respiratory infection, emerging data show that morbidity and mortality are driven by disseminated intravascular coagulopathy. Untreated CAC leads to microangiopathic thromboses, causing multiple systems organ failure and consuming enormous healthcare resources. Identifying strategies to prevent CAC are therefore crucial to reducing COVID-19 hospitalization rates. The pathogenesis of CAC is unknown, but there are major overlaps between severe COVID-19 and vitamin D insufficiency (VDI). We hypothesize that VDI is a major underlying contributor to CAC. Preliminary data from severe COVID-19 patients in New Orleans support this hypothesis. The purpose of the proposed multi-center, prospective, randomized controlled trial is to test the hypothesis that low-risk, early treatment with aspirin and vitamin D in COVID-19 can mitigate the prothrombotic state and reduce hospitalization rates.

NCT04363840 COVID Vitamin D Deficiency Coagulopathy Disseminated Intravascular Coagulation Drug: Aspirin 81 mg Dietary Supplement: Vitamin D
MeSH:Disseminated Intravascular Coagulation Vitamin D Deficiency
HPO:Disseminated intravascular coagulation Low levels of vitamin D

Primary Outcomes

Description: Hospitalization for COVID-19 symptoms

Measure: Hospitalization

Time: 2 weeks

2 Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients

The 2019 novel coronavirus disease (COVID-2019) pandemic is an enormous health issue of worldwide scale. Prevention and/or treatment with a widely-available and already-licensed product such as vitamin D (cholecalciferol) could have a large impact on healthcare worldwide. Given ethnic variation in vitamin D production, this could help to address the discrepancies in how people of different ethnicities are affected by COVID-19. There are currently no published studies analysing either individual-level evidence on the effect of vitamin D status on COVID-19 outcomes, or any prospective studies planning on following-up patients with reference to vitamin D and COVID-19 infection. The study will have 2 arms. Arm 1 will recruit patients hospitalised with COVID-19. Vitamin D levels will be measured in these patients and compared with outcome measures of COVID-19 severity. In Arm 2, patients will be recruited prospectively from local general practices (GPs) with measurement of vitamin D levels at enrolment. They will be followed up after 6 months to determine whether baseline vitamin D levels correspond with developing COVID-19. Data will be collected from a mixture of patient medical records, electronic patient records, laboratory data and from patients themselves. Data in Arm 1 will be analysed with a combination of linear and logistic regression, as appropriate, and with adjustment for covariates. Data in Arm 2 will be analysed as a case-control study, with adjustment for covariates. The primary objectives are to determine whether vitamin D levels affect outcomes in COVID-19 infection and whether vitamin D deficiency is associated with increased risk.

NCT04386044 COVID-19 Vitamin D Deficiency
MeSH:Vitamin D Deficiency
HPO:Low levels of vitamin D

Primary Outcomes

Description: Development of COVID-19 during case-control study

Measure: COVID-19 infection

Time: 1 year

Description: Whether hospitalised COVID-19 patients require oxygen therapy

Measure: Oxygen therapy for COVID-19

Time: 1 year

Description: Whether patients hospitalised with COVID-19 were discharged

Measure: Discharge following COVID-19 hospitalisation

Time: 1 year

Description: Whether patients hospitalised with COVID-19 died in hospital

Measure: Death due to COVID-19

Time: 1 year

HPO Nodes